We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

126 hedge funds and large institutions have $518M invested in Progenics Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $2.19M | Put options by funds: $1.05M

82% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 17

36% more capital invested

Capital invested by funds: $380M → $518M (+$138M)

10% more funds holding

Funds holding: 115 → 126 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 44

Holders
126
Holders Change
+11
Holders Change %
+9.57%
% of All Funds
3.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
36
Reduced
44
Closed
17
Calls
$2.19M
Puts
$1.05M
Net Calls
+$1.14M
Net Calls Change
+$693K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$19.7M
2
PWAM
Park West Asset Management
California
+$5.1M
3
GAM
Gotham Asset Management
New York
+$3.55M
4
Invesco
Invesco
Georgia
+$2.92M
5
BFA
BlackRock Fund Advisors
California
+$2.66M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$15.4M
2
Goldman Sachs
Goldman Sachs
New York
-$4.95M
3
State Street
State Street
Massachusetts
-$3.76M
4
BBA
Baker Bros. Advisors
New York
-$3.7M
5
KCM
Kennedy Capital Management
Missouri
-$3.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$2.38M +$2.04M +275,415 New
Charles Schwab
27
Charles Schwab
California
$2.38M -$157K -21,294 -7%
BIM
28
BlackRock Investment Management
Delaware
$2.36M -$3.81K -516 -0.2%
Goldman Sachs
29
Goldman Sachs
New York
$2.34M -$4.95M -669,130 -71%
AAP
30
Ardsley Advisory Partners
Connecticut
$2.33M -$1.4M -190,000 -41%
Allianz Asset Management
31
Allianz Asset Management
Germany
$1.82M -$78.6K -10,634 -5%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$1.81M – – –
TCIM
33
TIAA CREF Investment Management
New York
$1.75M -$647K -87,518 -30%
Wells Fargo
34
Wells Fargo
California
$1.73M +$940K +127,142 +173%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$1.71M +$1.36M +183,938 +1,345%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$1.55M -$68K -9,200 -5%
TC
37
TFS Capital
Pennsylvania
$1.51M +$1.29M +174,408 New
Citigroup
38
Citigroup
New York
$1.44M +$1.12M +151,321 +1,006%
GC
39
Globeflex Capital
California
$1.35M +$1.15M +155,898 +140,449%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$1.24M -$25.9K -3,500 -2%
Swiss National Bank
41
Swiss National Bank
Switzerland
$1M – – –
BIM
42
Bogle Investment Management
Massachusetts
$993K +$850K +115,008 New
TA
43
Teachers Advisors
New York
$967K +$20.5K +2,769 +3%
TI
44
Turner Investments
Pennsylvania
$946K -$501K -67,770 -38%
BA
45
BKS Advisors
Michigan
$926K -$1M -135,450 -56%
VEA
46
Virtus ETF Advisers
New York
$900K -$230K -31,127 -23%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$786K +$673K +91,035 New
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$771K -$1.25M -169,130 -65%
SO
49
STRS Ohio
Ohio
$741K +$404K +54,600 +175%
CS
50
Credit Suisse
Switzerland
$697K -$117K -15,864 -16%
1
2
3 4 5

PGNX Hedge Fund Activity: Q4 2016 in Review

126 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2016, worth a combined $518M — up 36% from $380M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PGNX positions and 17 closed out — a net gain of 14 holders — while 36 added to existing stakes and 44 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $19.7M. The largest seller was Millennium Management, cutting an estimated $15.4M.

  • 126 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2016, up from 115 in Q3 2016.
  • Funds reported $518M of Progenics Pharmaceuticals Inc stock for Q4 2016, up 36% quarter-over-quarter.
  • 31 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2016 and 17 closed out, a net change of +14 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2016 was Eagle Asset Management, an estimated $19.7M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2016 was Millennium Management, an estimated $15.4M sold.

Based on aggregated 13F filings for Q4 2016.